Johnson & Johnson (JNJ) EPS Estimated At $2.06

June 14, 2018 - By Tina Thibodeau

Johnson & Johnson (NYSE:JNJ) LogoInvestors sentiment increased to 0.93 in Q1 2018. Its up 0.06, from 0.87 in 2017Q4. It improved, as 63 investors sold Johnson & Johnson shares while 831 reduced holdings. 111 funds opened positions while 720 raised stakes. 1.71 billion shares or 0.80% less from 1.72 billion shares in 2017Q4 were reported.
Integral Derivatives Lc holds 0.04% of its portfolio in Johnson & Johnson (NYSE:JNJ) for 13,981 shares. Glenview Comml Bank Trust Dept invested in 4.3% or 71,259 shares. Ckw Financial Grp invested in 0.02% or 773 shares. Smith & Howard Wealth Mgmt Limited Liability Company reported 0.12% in Johnson & Johnson (NYSE:JNJ). Harvey Inv Lc, Kentucky-based fund reported 238,828 shares. Coastline Tru invested in 48,075 shares. Fishman Jay A Limited Mi reported 155,696 shares or 0% of all its holdings. Central Corp holds 85,000 shares or 1.8% of its portfolio. Cohen Klingenstein Ltd Liability holds 1.3% or 71,488 shares. Boston Common Asset Mngmt Limited Liability Company holds 98,243 shares. Horizon Investment Ser Ltd Limited Liability Company reported 3,087 shares. Essex Fincl Services holds 2.39% or 94,963 shares. Lincoln Cap Ltd Com has invested 2.23% of its portfolio in Johnson & Johnson (NYSE:JNJ). Chatham Capital accumulated 57,699 shares. Acropolis Inv Ltd Limited Liability Company stated it has 0.52% in Johnson & Johnson (NYSE:JNJ).

Since February 15, 2018, it had 0 buys, and 1 sale for $20.17 million activity.

Analysts expect Johnson & Johnson (NYSE:JNJ) to report $2.06 EPS on July, 17.They anticipate $0.23 EPS change or 12.57 % from last quarter’s $1.83 EPS. JNJ’s profit would be $5.53B giving it 14.86 P/E if the $2.06 EPS is correct. After having $2.06 EPS previously, Johnson & Johnson’s analysts see 0.00 % EPS growth. The stock decreased 0.18% or $0.22 during the last trading session, reaching $122.41. About 3.41M shares traded. Johnson & Johnson (NYSE:JNJ) has declined 4.75% since June 14, 2017 and is downtrending. It has underperformed by 17.32% the S&P500.

Johnson & Johnson (NYSE:JNJ) Ratings Coverage

Among 10 analysts covering Johnson & Johnson (NYSE:JNJ), 5 have Buy rating, 1 Sell and 4 Hold. Therefore 50% are positive. Johnson & Johnson had 19 analyst reports since January 2, 2018 according to SRatingsIntel. Stifel Nicolaus maintained Johnson & Johnson (NYSE:JNJ) on Wednesday, April 18 with “Hold” rating. The rating was downgraded by JP Morgan to “Neutral” on Tuesday, January 2. The company was upgraded on Thursday, April 12 by Credit Suisse. As per Tuesday, February 6, the company rating was maintained by Wells Fargo. On Tuesday, January 23 the stock rating was maintained by BTIG Research with “Sell”. As per Wednesday, April 18, the company rating was maintained by Wells Fargo. The firm has “Equal-Weight” rating given on Tuesday, April 10 by Morgan Stanley. The company was maintained on Friday, April 13 by Jefferies. The rating was maintained by Jefferies with “Buy” on Friday, March 23. The firm earned “Buy” rating on Friday, January 12 by Wells Fargo.

Johnson & Johnson, together with its subsidiaries, researches and develops, makes, and sells various products in the health care field worldwide. The company has market cap of $328.32 billion. It operates through three divisions: Consumer, Pharmaceutical, and Medical Devices. It has a 270.82 P/E ratio. The Consumer segment offers baby care products under the JOHNSONÂ’S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSONÂ’S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

More notable recent Johnson & Johnson (NYSE:JNJ) news were published by: which released: “Recent Purchase: Johnson & Johnson” on June 14, 2018, also with their article: “How Do You Feel About Johnson & Johnson?: Part IV – Today’s Editors’ Picks” published on June 01, 2018, published: “5 AI Biotech Stocks to Bet On Now” on June 14, 2018. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: and their article: “Johnson & Johnson (JNJ) Presents at Goldman Sachs 39th Annual Global Healthcare Conference Call (Transcript)” published on June 12, 2018 as well as‘s news article titled: “Better Buy: Verizon Communications Inc. vs. Johnson & Johnson” with publication date: June 11, 2018.

Johnson & Johnson (NYSE:JNJ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.